Abstract Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and
Introduction
Tumour growth and spread require angiogenesis. Understanding the molecular mechanisms by which tumour blood vessels develop in vivo is necessary for a better understanding of the drivers of tumour angiogenesis. Focal adhesion kinase (FAK) is a 125-kDa non-receptor tyrosine kinase involved in tumour angiogenesis [1, 2] .
Upon activation by various stimuli, including integrins and growth factors, FAK autophosphorylation at Y397 leads to binding and activation of Src, which in turn phosphorylates other FAK residues, including Y576, Y577, Y861, and Y925 [3, 4] . Apart from its role as a kinase, FAK also plays a role as a scaffolding protein, with binding sites for several proteins, making FAK a central player in cellular processes that include Endothelial FAK Y397E mutation and tumour vascular leakage 359 adhesion, migration, invasion, cell proliferation, and apoptosis [4, 5] .
We have previously shown that Pdgfb-iCre ertinducible endothelial cell (EC)-specific homozygous deletion of FAK leads to reduced primary tumour growth and angiogenesis [2] . Other reports have indicated that hemizygous EC-specific FAK kinase-dead (KD) mice show no effect on primary tumour growth, but show reduced vascular endothelial growth factor (VEGF)-stimulated vascular permeability [6] and metastasis [7] . These data have supported the development of pharmacological FAK kinase inhibitors. Indeed, inhibition of FAK kinase activity reduced vascular permeability and metastasis [6, 7] . Similar results were obtained with Src inhibitors and in Src-null mice [8] . FAK and Src may act in concert to regulate vascular permeability and metastasis [7] . Mice that are haploinsufficient for FAK expression show increased tumour growth and angiogenesis, indicating a dose-dependent role for FAK [9] , and this has raised the notion that homozygous FAK KD animals may show a different tumour angiogenic phenotype in vivo.
To further delineate which domains of FAK regulate these phenotypes in vivo, we have recently generated a series of endothelial-specific inducible mutant FAK knockin mice [10] . In this study, we used the FAK-K454R mutant, which is KD [11] , and a double mutant (DM) that carries both the KD mutation and a glutamate substitution of Y397 (Y397E), in order to test the requirement for FAK autophosphorylation and Src recruitment. Unlike previously published FAK-mutant mice, in our system, upon tamoxifen induction, Cre recombinase is activated in ECs, leading to deletion of endogenous FAK and expression of a myc-tagged knockin FAK under control of the Rosa26 (R26) promoter, in both alleles. Thus, after recombination in ECs, the endogenous FAK is replaced by the myc-tagged FAK, expressed under control of the R26 promoter, at a dose similar to that of endogenous FAK. As the knockin FAK is expressed under control of the R26 promoter, our system does not reflect any changes due to FAK promoter regulation [10] , as other models have [6, 7, 12] .
Materials and methods
Full information on the methods and reagents used in this study are available in supplementary materials and methods.
Mice
The work described was approved by the QMUL Ethics Committee. To study the effect of inducible EC-specific FAK mutations in vivo, we used a knockout/knockin system whereby endogenous mouse FAK was deleted and myc-tagged chicken FAK [ WT/WT mice expressed WT FAK, and were used to validate the system. The generation and characterization of these mice, together with proof of chicken FAK knockin, have been described previously [10] .
Tumour growth assays
Mice aged 12-16 weeks were given tamoxifen (Sigma, Irvine, UK) via intraperitoneal injection on two consecutive days; 3 days later, 10 6 B16F0 mouse melanoma cells (ATCC) were injected subcutaneously into the flanks of these mice. Mice were given a tamoxifen-containing diet (Tamoxifen400; Harlan Laboratories, Blackthorn, Bicester, UK), from the day of the second tamoxifen injection until the end of the experiment. Tumour sizes were measured with digital calipers on alternate days. Mice were killed by day 18 after tumour cell injection. Tumour volumes were calculated with the formula volume = length × width 2 × 0.52. Tumours were snap-frozen in isopentane chilled in liquid nitrogen. Four tumour growth experiments per genotype were performed.
Tumour immunohistochemistry
Counting and image analysis were performed with an epifluorescence Zeiss Axioplan Microscope (Zeiss, Munich, Germany). High-quality images were captured with a Carl Zeiss LSM 710 confocal microscope.
Blood vessel density
Frozen sections were fixed with cold acetone for 10 min, blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), incubated with a rat anti-endomucin antibody (clone V.7c7, 1:200; Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4 ∘ C, washed in PBS, and then incubated for 60 min at room temperature with an Alexa Fluor-labelled anti-rat antibody (A-21208, 1:200; Invitrogen, Loughborough, UK). Tumour blood vessels were counted across entire midline sections, and the numbers were expressed as vessels per mm 2 of tumour section.
Functional vessel analysis
Mice with size-matched tumours were tail vein-injected with 100 μl of 200 μg/ml phycoerythrin (PE)-conjugated anti-PECAM antibody (clone 390, neat; Biolegend, San Diego, CA, USA) 10 min before they were killed. To measure the percentage of functional vessels, tumour sections were stained for endomucin to identify all tumour blood vessels, and the percentage of endomucin-positive vessels that were PE-PECAM-perfused was calculated. 
Vascular permeability
Mice with size-matched tumours were tail vein-injected with 100 μl of 4 mg/ml Hoechst 33342 1 min before being killed, and with PE-conjugated anti-PECAM antibody as described above. Frozen tumour sections were fixed in cold acetone and mounted. Pictures of 5-10 fields were taken with a × 20 objective lens and analysed with Image J. Hoechst-positive areas divided by PE-PECAM-positive areas were calculated to give permeability ratios.
Hypoxia analysis
Pimonidazole-HCl (Hypoxyprobe, Burlington, MA, USA) at 60 mg/kg body weight was intraperitoneally injected 1 h before mice were killed. Frozen tumour sections were acetone-fixed, incubated overnight at 4 ∘ C with a fluorescein isothiocyanate-conjugated mouse anti-pimonidazole antibody (4.3.11.3, 1:10; Hypoxyprobe), and then washed and mounted. Sections were analysed at × 10 objective magnification, with 8-10 pictures per case. The percentage of hypoxic area over the total section area was calculated.
EC preparation
Mouse lung ECs were isolated from three adult mice per genotype, as previously described [13] . The purity of ECs prepared with our method has been established [2] . Anti-ICAM2 clone IC2/4 (3C4), (Abd Serotec, Martinsried, Germany); anti-VECAD clone 11D4.1; (BD Biosciences San Joe, CA, USA) were used to assess EC purity by flow cytometry on a Becton Dickinson, Oxford, UK, FACSCalibur instrument. As a negative control, IgG-matched isotypes were used (data not shown). Cells were immortalized by two rounds of infection with polyoma virus middle T [14] . To ensure maximal Cre-induced recombination, lung ECs isolated from Cre-positive mice were transfected with a Cre-encoding plasmid (pCAG-Cre-IRES2-GFP; Addgene, Cambridge, MA, USA 26646), and cells isolated from Cre-negative mice were transfected with the corresponding plasmid backbone (pCAG-GFP; Addgene 11150). Alternatively, immortalized cells were maintained in medium containing 500 nM 4-hydroxytamoxifen from day 4 after isolation. 
FAK immunoprecipitation and myc-tag western blotting

Results
We generated mouse lines to express a knockin WT chicken FAK ( Tamoxifen-treated Pdgfb-iCre ert -negative littermates were used as negative controls. WT chicken FAK has been shown to fully substitute for mouse FAK in other systems [15, 16] , and sequence homology within the nuclear localization motif and nuclear export signal sequences of mouse and chicken FAK suggests that the nuclear localizations of mouse and chicken FAK do not differ [17, 18] .
ECs were isolated from Cre-negative FAK fl/fl ; R26FAK Loss of EC FAK in adult mice reduces tumour growth and tumour angiogenesis [2] . To show that WT chicken FAK could reproduce the effects of endogenous mouse Figure 2C ). The salient features of tumour blood vessels were then analysed histologically, including blood vessel density, blood vessel perfusion, pericyte coverage, tumour hypoxia, and blood vessel leakage. Blood vessel density (number of endomucin-positive vessels per mm 2 of age-matched, size-matched tumour sections) was unchanged between B16F0 tumours grown in ECCre−;FAK WT/WT and ECCre+;FAK WT/WT mice ( Figure 2D ). To measure blood vessel perfusion, mice were injected ante mortem via the tail vein with a PE-labelled anti-PECAM antibody (PE-PECAM) to label perfused vessels. Tumour sections were then immunostained for endomucin to identify all vessels. Figure 2H ). Together, these data indicate that EC-specific WT myc-tagged chicken FAK knockin has no significant effect on tumour growth or tumour blood vessels, and confirms that the chicken FAK knockin can rescue the deleted mouse FAK in this system. We next sought to compare the in vivo effect of EC-specific FAK KD mutation, alone or in combination with the phosphomimetic Y397E mutation (in DM mice). Figure 4D ), suggesting that the KD mutation was sufficient to affect leakage.
The effect of a FAK Y397E mutation in combination with the KD mutation was then studied, in ECCre+;FAK DM/DM mice. Immunohistochemical analysis of tumour sections from ECCre−;FAK DM/DM and ECCre+;FAK DM/DM mice again showed no significant differences in blood vessel perfusion or NG2-positive pericyte association ( Figure 5A, B) , similarly to the results shown in Figure 4A , B. Analysis of tumour hypoxia showed that pimonidazole levels were higher in tumours grown in ECCre+;FAK DM/DM mice than in tumours grown in ECCre−;FAK DM/DM controls, correlating with the reduced blood vessel density observed in the tumours in ECCre+;FAK DM/DM mice ( Figure 5C ). In contrast to the results from the ECCre+;FAK KD/KD mice, blood vessel leakage of Hoechst dye was no different in ECCre+;FAK DM/DM mice from that in ECCre−;FAK DM/DM controls ( Figure 5D ), suggesting that the effect of the FAK KD mutation was overcome by the additional FAK Y397E mutation.
To begin to explain the changes in tumour growth and tumour blood vessels seen in ECCre+;FAK KD to attach to fibronectin for 5, 10 or 30 min, lysed, and subjected to Western blotting. As expected, attachment to fibronectin of Cre+;FAK WT/WT ECs induced phosphorylation of FAK on Y397, Y577, Y861, and Y925, and subsequent phosphorylation of the FAK/Src substrates paxillin and p130Cas. Surprisingly, we detected no fibronectin adhesion-dependent increase in phosphorylation of Src in this context. However, increased phosphorylation levels of direct Src substrates, such as FAK-Y577, FAK-Y861, and FAK-Y925, as well as p130Cas, clearly demonstrated that its kinase activity was stimulated. Cre+;FAK KD/KD ECs showed reduced phosphorylation of the FAK kinase target FAK-Y397 as expected, whereas sites of Src-dependent phosphorylation were unaffected, including FAK-Y577, FAK-Y861, FAK-Y925, and p130Cas-Y410. Introduction of the Y397E mutation into the DM FAK resulted in a super-inhibited form, and all the substrates tested showed greatly reduced phosphorylation, indicating that both FAK and Src activities were absent in these cells ( Figure 6A ). Phosphorylation of targets further down the signalling pathways, such as Akt and JNK1/2, was largely unaffected by either FAK mutant (supplementary material, Figure S2 ). Together, these data show a rather global effect on signalling, which does not explain why ECCre+;FAK DM/DM mice showed restored vascular leakage as compared with ECCre+;FAK KD/KD mice.
Probably the most studied regulator of vascular permeability is VECAD. Previous work has shown that KD FAK inhibits VECAD Y658 phosphorylation in vivo and that this is correlated with reduced vascular leakage [7] . ECs. These included β-actin, phospho-S636/639-IRS-1 (but not total IRS-1 levels), XIAP, Tyk2 pY1054/1055, and PLC-γ1, all of which are known to be mediators of Src signalling and regulators of permeability [20] [21] [22] [23] [24] [25] [26] [27] ( Figure 6C ). No changes in phosphorylation of VEGF receptor 2, another regulator of vascular permeability, were observed between any of the genotypes (supplementary material, Figure S3) 
Discussion
We showed previously that endothelial FAK is involved in tumour growth and angiogenesis [2] . However, genetic ablation of FAK did not allow us to determine whether this was due to FAK kinase or scaffolding activities. Our present data indicate that loss of FAK kinase activity in ECs leads to a similar phenotype as the total loss of FAK in ECs, regarding tumour formation, tumour angiogenesis, and tumour hypoxia [2] . This reveals the predominant role of FAK intrinsic kinase activity over its scaffolding functions in tumour growth. Interestingly, the Y397E substitution, designed as a phosphomimetic, was not able to rescue the tumour phenotype observed. However, the structures of phosphotyrosine and glutamate are very different, and it has been proposed before that there is no suitable phosphotyrosine phosphomimetic mutation [28] . The presence of glutamate at position Y397 of FAK may therefore not allow the binding and activation of Src and other FAK binding partners, which may explain why this mutant was unable to correct the KD phenotype. To explore this further, we investigated the phosphorylation of FAK and Src-dependent substrates in response to fibronectin attachment, a well-known FAK/Src stimulus [29] . However, we observed an increase in Src phosphorylation in our immortalized FAK KD ECs as compared with FAK WT cells. This has previously been observed in immortalized MEF KD cells but not in primary cells [12] . We also observed high basal levels of phospho-Src in WT cells, also possibly due to the immortalization, making phospho-Src an unreliable target to follow. We therefore explored the phosphorylation status of FAK-Y397, which depends on FAK kinase activity, and known Src targets [30] [31] [32] [33] [34] . Consistent with previous results, we observed no inhibition of Src activity in the FAK KD ECs [6] and only a reduction in pY397-FAK levels, confirming previous results showing that Src is able to phosphorylate this site independently of FAK kinase activity [35] . In the FAK DM ECs however, we observed a profound reduction in phosphorylation of all targets. In vitro, the DM ECs behaved very similarly to ECs expressing a mutated form of FAK in which exon 15, which codes for 19 amino acids, including Y397, was deleted (FAKΔ15) [36] . Whereas the trans-autophosphorylation activity and therefore the kinase activity of FAKΔ15 were unaffected, phosphorylation of FAK-Y576/77 and FAK-Y925, as well as p130Cas and paxillin, in response to fibronectin plating was absent in this mutant, similarly to what we observed with the FAK DM ECs. This strongly supports the hypothesis that, in this DM, the glutamate substitution actually profoundly disrupted Src activation. This is in agreement with previous studies showing the importance of Y397 as a binding site for Src, rather than in FAK kinase activation, and the need for both kinases to act as a complex for efficient phosphorylation of substrates [32] . Interestingly, there was a reduction in vascular leakage in the ECCre+;FAK KD/KD mouse tumour vessels that was, however, corrected in the vessels of the ECCre+;FAK DM/DM mice. Both FAK and Src kinases activities have been previously shown to regulate VEGF-induced permeability in vivo, with a reduction in vascular permeability in response to genetic deletion of FAK or Src, or in response to pharmacological inhibitors of these targets [6, 37] . Surprisingly, in our study, inhibition of both kinases together reversed this decreased permeability. This suggests that, whereas inhibition of either kinase alone is sufficient to modulate EC barrier strengthening, Src and FAK probably act as a complex in this process, and either need each other's kinase activity or, as has been suggested in previous reports, regulate each other's intracellular localization and thereby downstream signalling [7, 32, 38] [20] [21] [22] [23] [24] [25] [26] [27] , and the changes observed correlate with reduced leakage in ECCre+;FAK KD/KD mice that is rescued in ECCre+;FAK DM/DM mice. Together, these results suggest that FAK kinase activity and Src work in concert to control VECAD activity and upstream molecular pathways.
Our data regarding tumour formation differ from the data in a 2014 study [7] , in which it was shown that FAK KD expression in the endothelium leads to reduced metastasis without affecting primary tumour growth. One should, however, keep in mind the differences between the mouse models used in these studies, as others have used a system in which FAK mutants are expressed in a hemizygous state, whereas, in our current study, FAK mutants are expressed by both alleles.
The role of FAK as a dose-dependent regulator of angiogenesis has previously been stressed. FAK heterozygous mice do not phenocopy WT FAK mice, and, in fact, show enhanced tumour angiogenesis and tumour growth [9] . Thus, as the mice in the above study [7] are hemizygous for WT or KD FAK (and not homozygous, as ours are), this may explain the difference in the results.
We have used EC-specific FAK knockin mutants homozygously expressed to help determine the roles of the kinase domain and Y397 residue in vivo in tumour growth and angiogenesis. Overall, our data show that inhibiting FAK kinase activity in ECs is sufficient to reduce tumour growth and angiogenesis, and strongly support the use of FAK inhibitors in the clinic [39] . The reduction in vascular leakage observed in ECCre+;FAK KD/KD mice suggests that these inhibitors might have additional positive effects in vivo, as they would be expected to reduce vascular permeability, and therefore improve normalization and drug delivery, and also potentially reduce metastasis [7, 40] . Outside the context of oncology, it would be interesting to test the effects of FAK kinase inhibitors in ischaemic tissues, where VEGF-induced permeability has deleterious consequences, exacerbating tissue injury and infarct size [40] . The use of other knockin mutants should help to further delineate FAK signalling in physiological and pathological processes in vivo.
